Nanobiotix Announces the Presentation of the Final Efficacy
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at...
Source: globenewswire.com
Bernard Doger News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Bernard Doger. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Bernard Doger Today - Breaking & Trending Today
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort ...
Final data from Study 102 Dose Expansion show that radiotherapy-activated NBTXR3 was feasible and well tolerated in elderly patients with a high burden of comorbidity (n=56)Consistently high injected-lesion overall response
Source: clintonherald.com
Nanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months
Results presented in an oral presentation by Professor Christophe Le Tourneau, MD, PhD, of Institut Curie, and highlighted in two scientific sessions at the 65th Annual Meeting of the American Society...
Source: marketscreener.com
Transgene Presents Data From Phase I Clinical Trial Confirming the Potential of the Oncolytic Virus TG6002
Press release content from Business Wire. The AP news staff was not involved in its creation.
Source: apnews.com
Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses
Press release content from Business Wire. The AP news staff was not involved in its creation. Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses April 9, 2021 GMT Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, today announces initial promising results from a Phase I study combining intravenous (IV) oncolytic virus TG6002 and oral 5-FC in patients with advanced gastrointestinal carcinomas. These data prov...
Source: apnews.com